LR19157
AML
Pre-clinicalActive
Key Facts
About AVEO Oncology
AVEO Oncology is a clinical-stage biopharmaceutical company specializing in targeted cancer therapies, operating as a U.S. subsidiary of South Korea's LG Chem. The company has one FDA-approved product, FOTIVDA for renal cell carcinoma, and a diverse early-to-mid-stage pipeline focused on monoclonal antibodies and novel mechanisms. Its business model centers on in-licensing, co-development, and commercialization, aiming to grow into a global oncology leader by leveraging LG Chem's resources and strategic partnerships.
View full company profileTherapeutic Areas
Other AML Drugs
| Drug | Company | Phase |
|---|---|---|
| ZE46-0134 (lomonitinib) | Eilean Therapeutics | IND-Enabling |
| ZE50-0134 (lonitoclax) | Eilean Therapeutics | Discovery |
| ZE63-0302 (balomenib) | Eilean Therapeutics | Discovery |
| High Internalization ADC | Lytica Therapeutics | Preclinical |
| CAR-T (Allogeneic) | Wugen | Clinical |